← Back to all trials
Not Yet Recruiting
NCT07823075
Efficacy and Safety of Intrapleural Fibrinolytic Therapy in Tuberculous Pleural Effusion Versus Non-Tuberculous Pleural Infection
Conditions: Tuberculous Pleural Effusion
Sex: All
Ages: 18 Years – 85 Years
Healthy volunteers: No
Enrollment: 160
Sponsor: National University of Malaysia
Location: National University of Malaysia Kuala Lumpur Kuala Lumpur
Summary
This retrospective cohort study evaluates the efficacy and safety of intrapleural fibrinolytic therapy (tPA/DNase) in patients with tuberculous pleural effusion compared with non-tuberculous pleural infection at Hospital Canselor Tuanku Muhriz (HCTM), Malaysia. The study aims to compare radiological improvement, clinical outcomes, and treatment-related adverse events to provide evidence supporting the use of IPFT in tuberculous pleural effusion.
Eligibility Criteria
Inclusion Criteria:
1. Adults aged ≥18 years.
2. Patients with tuberculous pleural effusion or non-tuberculous pleural effusion diagnosed based on clinical, radiological, laboratory, microbiological, histopathological, and/or pleuroscopic findings.
3. Patients who received intrapleural fibrinolytic therapy with tissue plasminogen activator and deoxyribonuclease during the study period.
Exclusion Criteria:
1. Malignant and transudative pleural effusion
2. Patients who received intrapleural fibrinolytic therapy as monotherapy with either tissue plasminogen activator or deoxyribonuclease alone.
3. Incomplete medical records
Source: ClinicalTrials.gov (NCT07823075). StuddyBuddy aggregates publicly available trial information.
